Saturday, October 31, 2026

TrueBlue Stock Bearish By 17% So Far On Tuesday

TrueBlue Stock Bearish By 17% So Far On Tuesday

TrueBlue (NYSE: TBI), a reputable staffing company listed on the New York Stock Exchange recently experienced a stark decrease of 17.26%, rendering a stock price of just $0.13. This marked a noteworthy occurrence, considering that the shares have been low since the preceding February. TrueBlue's diverse service offerings through segments such as PeopleReady, PeopleManagement, and PeopleScout provide comprehensive workforce solutions in numerous countries. Nevertheless, the company's expansive portfolio does not provide immunity against market volatility.

Performance and Investor perception

Over the past 12 months, TrueBlue's earnings per share (EPS) landed at $0.4, casting a positive light on the value or prospective growth of the firm in the eyes of investors. Furthermore, the PE Ratio of TrueBlue's stocks indicates that investors were willing to commit $10.81 in return for each dollar of annual earnings. This ratio paints a picture of how the company is valued by investors.

Shareholders Return and Return on Equity

In 2017, TrueBlue demonstrated a return on equity of 10.15% for its shareholders. This return rate signifies how effectively the company was able to generate profit using shareholders' equity. However, investors may want to exercise caution given that the company's value has dropped significantly below its 50-day moving average of $0.37 and 200-day moving average of $0.60.

Sentiment and Volatility

Despite last week's intraday variation average of -1.19%, TrueBlue showed a positive trend over an extended period. However, it's high volatility, reaching 1.70%, may discourage risk-averse investors considering other more stable investment options.

Future Growth Projections

The company's growth projections also serve as a cause of concern, as it anticipates negative growth of 73.2% this quarter and 58.7% in the upcoming one. These figures may contribute to the current stock drop and its volatile nature.

Conclusion

In conclusion, it appears that TrueBlue's stock performance may be primarily influenced by its lagging moving averages, high volatility, and negative growth forecasts. While some risk-tolerant investors might perceive potential trading opportunities under ideal conditions, those seeking stability might prefer to proceed with caution.

More news about TrueBlue (TBI).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com